Form Type:  8-K
Filing Date:  6/16/2020 
CIK:  0001537917 
Address:  1 PLUCKEMIN WAY - SUITE 103 
City, State, Zip:  BEDMINSTER, New Jersey 07921 
Telephone:  212-461-2315 
Fiscal Year:  03/31 
Last Trade
Last Trade: 
0.0239 (2.57%)  
Trade Time: 
Sep 25  
Market Cap: 
Trade TYME now with

© 2020  
Description of Business
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients' quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific pathways within cancer, TYME's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic requirements to cause cancer cell death. Our first-in-class CMBT compounds include SM-88 and TYME-18. These compounds are structurally and mechanistically different, and we believe they offer the potential for better and safer medicines. Early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of our emerging CMBT pipeline.
Register and access this filing in:     
  FORM 8-K
      Item 8.01 Other Events.